Recently, Tianjin Jin Yao Pharmaceutical Co., Ltd, a subsidiary of Tianjin Tianyao Pharmaceuticals Co.,Ltd., received the Notice of Approval for Drug Supplementary Application approved and issued by National Medical Products Administration for Mecobalamine Injection, approving the drug to pass the consistency evaluation of generic drug quality and efficacy.

It is understood that mecobalamin injection is mainly used to treat megaloblastic anemia caused by vitamin B12 deficiency, and peripheral neuropathy. The "qualification" of drug this time means that the domestic market advantage of the preparation products of Tianjin Tianyao Pharmaceuticals Co.,Ltd. is further expanded. The company's competitiveness, especially in the billion-dollar market of mecobalamin injection, is further enhanced. Up to now, the company has more than 10 products passed the consistency evaluation one after another;

At present, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has more than 100 research projects in research, involving many therapeutic fields such as immune system, respiratory system, cardiovascular and cerebrovascular diseases and anti-tumor. With the landing of these pharmaceutical research projects, Tianjin Tianyao Pharmaceuticals Co.,Ltd. will open up market space and create conditions for the company's sustainable and benign development.